

Table of Contents

1. CHC Market – Situation Report

- a) 2014-18
- b) What happened in 2018
- c) North America
- d) Europe
- e) Japan
- f) Australasia
- g) Model 1 (DtC) vs 2 (OTx)

2. Emerging Markets

- a) Overview
- b) BRICITS
- c) 2nd tier (Poland, Mexico, etc)
- d) The new 3rd tier (Iran, Saudi Arabia, etc)
- e) How to succeed in the Emerging Markets

3. Healthcare Trends

- a) Increases in allergy, obesity, diabetes, autism, ADHD, etc.
- b) Medical provision
- c) State vs private medicine
- d) Big Pharma
- e) Influences on the consumer

4. Engaging with the Consumer

- a) Demographics
- b) Lifestyle
- c) Prevention
- d) The Ageing Consumer
- e) Women vs Men
- f) The declining birthrate
- g) Shopper insights

5. Innovation

- a) Why CHC isn't innovating
- b) Recent best practice
- c) New delivery systems
- d) Medical devices
- e) Diagnostics

6. Regulation

- a) The overall trend to deregulation and reregulation
- b) Harmonisation vs regional differences
- c) FDA
- d) New medical device legislation

7. Rx-to-OTC Switch

- a) Why switch?
- b) Switch models
- c) USA vs ROW: Can switch be profitable only in USA?
- d) Recent switches: what went right / what went wrong?

- e) Europe's central procedure
- f) Advisory OTCs
- g) What's coming down the pipeline
- h) Changes to healthcare structure
- i) Key Performance Indicators

8. Adjacent Categories

- a) Sexual health
- b) Medical cannabis
- c) Smoking control / e-cigarettes
- d) Obesity & diabetes
- e) Nutraceuticals & nutritionals
- f) Food intolerance
- g) Cosmeceuticals
- h) Natural products
- i) Immunity and detox
- j) Sleeping disorders
- k) Mental health, mood & stress

9. Distribution

- a) Dealing with powerful chains
- b) The challenge of global retailers
- c) Pharmacy buying groups
- d) Private label
- e) Retail Category Management
- f) Technology – how retailers use info gleaned from consumers

10. Pharmacy Point-of-Care

- a) Pharmacy – the bedrock of the OTC market
- b) Evolution of pharmacy
- c) PPoC – turning pharmacies into health centres
- d) Third Class in the USA
- e) In-Store Clinics – a USA Phenomenon

11. e-Commerce

- a) Information
- b) Influence
- c) A product to be sold

12. Direct Selling

- a) Why does MLM have such high growth?
- b) Network / Multi-Level Marketing
- c) The Internet of Things and for Sales

13. The Rainbow Effect

- a) Classic media is losing traction
- b) Digital marketing
- c) PR, Word-of-Mouth
- d) Guerilla marketing / Viral / Spectacular
- e) Consumers – do we know their names?
- f) Medical marketing
- g) Detailing pharmacists
- h) A million new ambassadors – pharmacy staff, nurses, auxiliaries

14. Digital Engagement

- a) Internet
- b) Big Tech (GAFA)
- c) Social Media – fans own it
- d) Marketer-driven content
- e) How consumers are finding out about brands
- f) How it can all go wrong

15. Competition

- a) Why are the MNCs underperforming?
- b) Key regional / local marketers
- c) Winners, Survivors & Losers
- d) Profiles of 20 top players
- e) Stars of the future

16. M&A

- a) Are CHC acquisitions always a sideshow of Big Pharma?
- b) Does M&A work?
- c) Multiples
- d) Buyers & Sellers
- e) Role of private equity
- f) Recent healthcare M&A deals

17. Managing Brands For Long-Term Profit Growth

- a) Building brand values, strengthening consumer loyalty
- b) Is the CHC industry already generic?
- c) Adding value, raising prices
- d) International price comparisons
- e) Umbrella branding and line extensions
- f) CHC profitability
- g) Building critical mass on a global scale

18. Success Factors

- a) The ideal CHC organisation
- b) Brand success matrix
- c) Looking after our people
- d) Social responsibility
- e) 10 Dos & 10 Don'ts

19. Case Studies of Success (& Failure)

- o Case studies dotted throughout report

20. Looking Over the Horizon

- a) Disruption – Big Pharma, Big Tech, generics
- b) The most likely case
- c) The best case
- d) Strategy options
- e) Creative solutions
- f) Forecasts 2025, 2030 – a full Valuation Model
- g) Why invest in CHC?
- h) ... And finally